Boston Scientific (BSX) Stock Forecast & Price Target $97.72 +0.01 (+0.01%) Closing price 03:59 PM EasternExtended Trading$97.42 -0.30 (-0.31%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating BuyBased on 27 Analyst RatingsSell0Hold2Buy25 Based on 27 Wall Street analysts who have issued ratings for Boston Scientific in the last 12 months, the stock has a consensus rating of "Buy." Out of the 27 analysts, 2 have given a hold rating, 23 have given a buy rating, and 2 have given a strong buy rating for BSX. Consensus Price Target $120.7123.52% Upside According to the 27 analysts' twelve-month price targets for Boston Scientific, the average price target is $120.71. The highest price target for BSX is $136.00, while the lowest price target for BSX is $100.00. The average price target represents a forecasted upside of 23.52% from the current price of $97.72. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for BSX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Boston Scientific and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BSX Analyst Ratings Over TimeTypeCurrent Forecast10/16/24 to 10/16/251 Month Ago9/16/24 to 9/16/253 Months Ago7/18/24 to 7/18/251 Year Ago10/17/23 to 10/16/24Strong Buy2 Strong Buy rating(s)3 Strong Buy rating(s)3 Strong Buy rating(s)1 Strong Buy rating(s)Buy23 Buy rating(s)22 Buy rating(s)21 Buy rating(s)17 Buy rating(s)Hold2 Hold rating(s)1 Hold rating(s)0 Hold rating(s)2 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$120.71$118.04$116.09$88.55Forecasted Upside23.52% Upside19.27% Upside11.97% Upside1.76% UpsideConsensus RatingBuyBuyBuyModerate Buy BSX Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History BSX Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Boston Scientific Stock vs. The CompetitionTypeBoston ScientificMedical CompaniesS&P 500Consensus Rating Score 3.00 2.33 2.52Consensus RatingBuyHoldModerate BuyPredicted Upside23.48% Upside1,107.41% Upside13.54% UpsideNews Sentiment RatingPositive NewsSee Recent BSX NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/8/2025Weiss Ratings0 of 5 stars Reiterated RatingBuy (B-)10/7/2025Evercore ISI3 of 5 starsVijay Kumar Not RatedLower TargetOutperform$115.00 ➝ $110.00+13.72%10/3/2025Erste Group Bank3 of 5 stars DowngradeBuy ➝ Hold10/2/2025BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatt MiksicSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$133.00 ➝ $136.00+42.00%10/1/2025Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingWilliam PlovanicSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$131.00 ➝ $132.00+35.32%10/1/2025Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRichard NewitterSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$125.00 ➝ $129.00+37.12%10/1/2025Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMike KratkySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOutperform$127.00 ➝ $128.00+31.21%10/1/2025Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid RescottSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOutperform$123.00 ➝ $128.00+31.21%10/1/2025BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMarie ThibaultSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$127.00 ➝ $132.00+35.32%10/1/2025Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMike MatsonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$121.00+24.04% Get the Latest News and Ratings for BSX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter. 9/29/2025Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingShagun SinghSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform$125.00+28.48%9/8/2025OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSteven LichtmanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$118.00 ➝ $125.00+16.67%7/24/2025Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJayson BedfordSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetStrong-Buy$121.00 ➝ $124.00+17.45%7/24/2025UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDanielle AntalffySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$130.00 ➝ $135.00+27.80%7/24/2025Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLarry BiegelsenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$118.00 ➝ $124.00+17.74%7/21/2025Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingHold6/16/2025Leerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingM. KratkySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy5/22/2025CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJoanne WuenschSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$119.00 ➝ $125.00+19.59%5/16/2025Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingPatrick WoodSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$120.00 ➝ $125.00+18.58%2/18/2025ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Set Target$130.00+24.98%2/6/2025Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRick WiseSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$100.00 ➝ $115.00+9.25%2/3/2025Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatt O'BrienSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$95.00 ➝ $115.00+11.65%1/10/2025Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeHold ➝ Buy$108.00+12.64%12/16/2024JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetOverweight$100.00 ➝ $110.00+21.21%12/12/2024TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$100.00 ➝ $110.00+21.11%10/24/2024Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetOutperform$92.00 ➝ $100.00+16.41%10/24/2024MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetOutperform$100.00 ➝ $110.00+25.79%10/22/2024Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$90.00 ➝ $100.00+13.39%5/30/2024The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Initiated CoverageBuy$90.00+20.05%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:44 PM ET. Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 15, 2025. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com. Boston Scientific Bull Case Here are some ways that investors could benefit from investing in Boston Scientific Co.: Recent analyst upgrades have increased the target price for Boston Scientific Co. to as high as $135.00, indicating strong market confidence in the company's growth potential. The current stock price is around $96.73, which may present a buying opportunity for investors looking to enter at a lower price point compared to its one-year high of $109.50. Boston Scientific Co. has a solid market capitalization of approximately $143.33 billion, reflecting its strong position in the medical device industry. Insider activity shows significant sales, but insiders still hold only 0.50% of the company's stock, suggesting that there may be confidence in the company's future performance despite recent sales. The company has received multiple "buy" ratings from analysts, with a consensus rating of "Buy," which can be a positive indicator for potential investors. Boston Scientific Bear Case Investors should be bearish about investing in Boston Scientific Co. for these reasons: Recent insider sales, including a significant transaction by an executive vice president, may raise concerns about the company's short-term outlook and insider confidence. Despite a strong market position, the company's price-to-earnings (P/E) ratio of 57.58 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors. Analysts have also issued some downgrades, with one firm lowering its price target from $115.00 to $110.00, indicating potential volatility in stock performance. The company has a relatively high price-to-earnings-growth (PEG) ratio of 2.31, which may indicate that the stock is priced high relative to its expected growth rate, making it less attractive for growth investors. Market fluctuations and economic uncertainties could impact the performance of Boston Scientific Co., as seen in the broader market trends affecting the healthcare sector. BSX Forecast - Frequently Asked Questions What is Boston Scientific's forecast for 2025? According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Boston Scientific is $120.71, with a high forecast of $136.00 and a low forecast of $100.00. Should I buy or sell Boston Scientific stock right now? 27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last twelve months. There are currently 2 hold ratings, 23 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BSX shares. Does Boston Scientific's stock price have much upside? According to analysts, Boston Scientific's stock has a predicted upside of 23.52% based on their 12-month stock forecasts. Has Boston Scientific been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, Boston Scientific's stock had 1 upgrade and 1 downgrade by analysts. What analysts cover Boston Scientific? Boston Scientific has been rated by research analysts at Barclays, BTIG Research, Canaccord Genuity Group, Erste Group Bank, Evercore ISI, Jefferies Financial Group, Leerink Partners, Needham & Company LLC, Oppenheimer, Raymond James Financial, Robert W. Baird, Royal Bank Of Canada, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days. Do Wall Street analysts like Boston Scientific more than its competitors? Analysts like Boston Scientific more than other "medical" companies. The consensus rating for Boston Scientific is Buy while the average consensus rating for "medical" companies is Hold. Learn more on how BSX compares to other companies. Stock Forecasts and Research Tools Related Companies ALGN Stock Forecast HOLX Stock Forecast HQY Stock Forecast MMSI Stock Forecast AMN Stock Forecast CAH Stock Forecast DVA Stock Forecast ECL Stock Forecast HCA Stock Forecast MDT Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NYSE:BSX) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredWall St’s “AI Godfather” breaks his silenceWhats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Boston Scientific Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Boston Scientific With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
